190 related articles for article (PubMed ID: 30128854)
1. Significance of introduction of alternative dosing schedule for sunitinib during first-line treatment of patients with metastatic renal cell carcinoma.
Miyake H; Matsushita Y; Watanabe H; Tamura K; Suzuki T; Motoyama D; Ito T; Sugiyama T; Otsukav A
Med Oncol; 2018 Aug; 35(10):133. PubMed ID: 30128854
[TBL] [Abstract][Full Text] [Related]
2. Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial.
Mouillet G; Paillard MJ; Maurina T; Vernerey D; Nguyen Tan Hon T; Almotlak H; Stein U; Calcagno F; Berthod D; Robert E; Meurisse A; Thiery-Vuillemin A
Trials; 2018 Apr; 19(1):221. PubMed ID: 29650037
[TBL] [Abstract][Full Text] [Related]
3. Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib.
Miyake H; Harada K; Miyazaki A; Fujisawa M
Med Oncol; 2015 Mar; 32(3):78. PubMed ID: 25698532
[TBL] [Abstract][Full Text] [Related]
4. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off.
Kondo T; Takagi T; Kobayashi H; Iizuka J; Nozaki T; Hashimoto Y; Ikezawa E; Yoshida K; Omae K; Tanabe K
Jpn J Clin Oncol; 2014 Mar; 44(3):270-7. PubMed ID: 24474815
[TBL] [Abstract][Full Text] [Related]
5. The Alternative 2/1 Schedule of Sunitinib is Superior to the Traditional 4/2 Schedule in Patients With Metastatic Renal Cell Carcinoma: A Meta-analysis.
Sun Y; Li J; Yang X; Zhang G; Fan X
Clin Genitourin Cancer; 2019 Oct; 17(5):e847-e859. PubMed ID: 31279483
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib 4/2 Versus 2/1 Schedule for Patients With Metastatic Renal Cell Carcinoma: Tertiary Care Hospital Experience.
Ezz El Din M
Clin Genitourin Cancer; 2017 Jun; 15(3):e455-e462. PubMed ID: 28392154
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes associated with different sunitinib dosing regimens in metastatic renal cell carcinoma.
Cheng W; Kletas V; Kollmannsberger C; de Lemos M
J Oncol Pharm Pract; 2020 Jan; 26(1):67-73. PubMed ID: 30909792
[TBL] [Abstract][Full Text] [Related]
8. [A pilot study of sunitinib as first-line therapy for metastatic renal cell carcinoma on a 2 weeks on/1 week off intermittent dosing schedule].
Cui C; Li S; Chi Z; Si L; Sheng X; Mao L; Lian B; Wang X; Tang B; Guo J
Zhonghua Zhong Liu Za Zhi; 2015 May; 37(5):375-8. PubMed ID: 26463030
[TBL] [Abstract][Full Text] [Related]
9. [Dosing Schedules and Outcomes in Patients Treated with First-Line Sunitinib for Advanced Renal Cell Carcinoma].
Inoue R; Kitamura H; Shindo T; Nishiyama N; Masumori N
Hinyokika Kiyo; 2016 Apr; 62(4):173-7. PubMed ID: 27217010
[TBL] [Abstract][Full Text] [Related]
10. Results of weekday-on and weekend-off administration schedule of sunitinib therapy for advanced renal cell carcinoma.
Kawashima A; Uemura M; Kato T; Ujike T; Nagahara A; Fujita K; Imamura R; Yamanaka Y; Tomiyama E; Tanigawa G; Miyagawa Y; Yoshioka T; Miyake O; Nonomura N
Int J Clin Oncol; 2019 Jan; 24(1):78-86. PubMed ID: 30094693
[TBL] [Abstract][Full Text] [Related]
11. Association of sunitinib concentration and clinical outcome in patients with metastatic renal cell carcinoma treated with a 2-week-on and 1-week-off schedule.
Ito T; Yamamoto K; Furukawa J; Harada K; Fujisawa M; Omura T; Yano I
J Clin Pharm Ther; 2022 Jan; 47(1):81-88. PubMed ID: 34669974
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma.
Iwamoto K; Ishihara H; Takagi T; Kondo T; Yoshida K; Iizuka J; Tanabe K
Med Oncol; 2018 Apr; 35(6):78. PubMed ID: 29687160
[TBL] [Abstract][Full Text] [Related]
13. Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma.
Guida FM; Santoni M; Conti A; Burattini L; Savini A; Zeppola T; Caricato M; Cascinu S; Tonini G; Santini D
Crit Rev Oncol Hematol; 2014 Dec; 92(3):208-17. PubMed ID: 25151214
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
Barrios CH; Hernandez-Barajas D; Brown MP; Lee SH; Fein L; Liu JH; Hariharan S; Martell BA; Yuan J; Bello A; Wang Z; Mundayat R; Rha SY
Cancer; 2012 Mar; 118(5):1252-9. PubMed ID: 21898376
[TBL] [Abstract][Full Text] [Related]
15. Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma.
Jonasch E; Slack RS; Geynisman DM; Hasanov E; Milowsky MI; Rathmell WK; Stovall S; Juarez D; Gilchrist TR; Pruitt L; Ornstein MC; Plimack ER; Tannir NM; Rini BI
J Clin Oncol; 2018 Jun; 36(16):1588-1593. PubMed ID: 29641297
[TBL] [Abstract][Full Text] [Related]
16. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
Shi HZ; Tian J; Chen X; Wang D; Li CL
Clin Genitourin Cancer; 2017 Feb; 15(1):139-144. PubMed ID: 27338518
[TBL] [Abstract][Full Text] [Related]
17. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.
Najjar YG; Mittal K; Elson P; Wood L; Garcia JA; Dreicer R; Rini BI
Eur J Cancer; 2014 Apr; 50(6):1084-9. PubMed ID: 24559686
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
19. Outcomes and Drug Costs of Sunitinib Regimens for Metastatic Renal Cell Carcinoma: A Provincial Population-Based Study.
Suo A; Iqbal U; Lim J; Lee C; Gesy K; Iqbal N; Abbas T
Clin Genitourin Cancer; 2017 Jun; 15(3):e397-e404. PubMed ID: 28216279
[TBL] [Abstract][Full Text] [Related]
20. How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma.
Bracarda S; Negrier S; Casper J; Porta C; Schmidinger M; Larkin J; Gross Goupil M; Escudier B
Expert Rev Anticancer Ther; 2017 Mar; 17(3):227-233. PubMed ID: 28044472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
